The Need for Identifying Standardized Indices for Measuring Glucose Variability

Siegelaar SE Barwari T Kulik W Hoekstra JB DeVries HJ . No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol. 2011;5 (1): 86–92.

Di Flaviani A Picconi F Di Stefano P Giordani I Malandrucco I Maggio P Palazzo P Sgreccia F Peraldo C Farina F Frajese G Frontoni S . Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care. 2011;34 (7): 1605–9. Epub 2011 May 24.

Cameron FJ Donath SM Baghurst PA . Measuring glycaemic variation. Curr Diabetes Rev. 2010;6 (1): 17–26.

De Caterina R Cipollone F Filardo F P Zimarino M Bernini W Lazzerini G Bucciarelli T Falco A Marchesani P Muraro R Mezzetti A Ciabattoni G . Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: No further effect of vitamin E. Circulation. 2002;106 (20): 2543–9.

Giaccari A Sorice G Muscogiuri G . Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes — Mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis. 2009;19 (5): 365–77. Epub 2009 May 9.

Proudfoot J Barden A Mori TA Burke V Croft KD Beilin LJ Puddey IB . Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999 Aug 1; 272 (2): 209–15.